基于价值的医学与眼科：成本效用分析评估
Value-based medicine and ophthalmology: an appraisal of cost-utility analyses.
作者信息
Brown Gary C, Brown Melissa M, Sharma Sanjay, Brown Heidi, Smithen Lindsay, Leeser David B, Beauchamp George
机构信息
Center for Value-Based Medicine, Flourtown, Pennsylvania, USA.
出版信息
Trans Am Ophthalmol Soc. 2004;102:177-85; discussion 185-8.
PURPOSE
To ascertain the extent to which ophthalmologic interventions have been evaluated in value-based medicine format.
METHODS
Retrospective literature review. Papers in the healthcare literature utilizing cost-utility analysis were reviewed by researchers at the Center for Value-Based Medicine, Flourtown, Pennsylvania. A literature review of papers addressing the cost-utility analysis of ophthalmologic procedures in the United States over a 12-year period from 1992 to 2003 was undertaken using the National Library of Medicine and EMBASE databases. The cost-utility of ophthalmologic interventions in inflation-adjusted (real) year 2003 US dollars expended per quality-adjusted life-year (dollars/QALY) was ascertained in all instances.
RESULTS
A total of 19 papers were found, including a total of 25 interventions. The median cost-utility of ophthalmologic interventions was 5,219 dollars/QALY, with a range from 746 dollars/QALY to 6.5 million dollars/QALY.
CONCLUSIONS
The majority of ophthalmologic interventions are especially cost-effective by conventional standards. This is because of the substantial value that ophthalmologic interventions confer to patients with eye diseases for the resources expended.
目的
确定眼科干预措施在基于价值的医学模式下的评估程度。
方法
回顾性文献综述。宾夕法尼亚州弗洛敦市基于价值的医学中心的研究人员对医疗保健文献中使用成本效用分析的论文进行了综述。利用美国国立医学图书馆和EMBASE数据库，对1992年至2003年这12年间美国眼科手术成本效用分析的论文进行了文献综述。在所有情况下，均确定了以2003年经通胀调整（实际）的美元计算的眼科干预措施的成本效用，即每质量调整生命年所花费的美元数（美元/质量调整生命年）。
结果
共找到19篇论文，包括25项干预措施。眼科干预措施的成本效用中位数为5219美元/质量调整生命年，范围从746美元/质量调整生命年至650万美元/质量调整生命年。
结论
按照传统标准，大多数眼科干预措施具有特别的成本效益。这是因为眼科干预措施为眼病患者带来的价值与所耗费的资源相比非常可观。
Zotero 插件